



ARKG

ARK GENOMIC REVOLUTION UCITS ETF



FUND DESCRIPTION

The ARK Genomic Revolution ETF (“ARKG”) seeks to invest in companies that are substantially focused on or benefit from extending and enhancing quality of life by incorporating technological developments and scientific advancements in genomics into their business. They offer new products or services that rely on genomic sequencing, analysis, synthesis or instrumentation. These companies span sectors, from healthcare to IT and beyond. They may also develop, produce, manufacture or rely on or enable bionic devices, bio-inspired computing, bioinformatics, molecular medicine and agricultural biotechnology.

WHY INVEST IN ARKG?



Exposure to Innovation: Aims for thematic multi-cap exposure to innovative elements including gene therapy bio-informatics, bio-inspired computing, molecular medicine, and pharmaceutical innovations. ARK believes the securities held in ARKG present the best risk-reward opportunities from ARK’s Genomic Revolution theme.



Growth Potential: Aims to capture long-term growth with low correlation to relative returns to traditional growth strategies and negative correlation to value strategies.



Tool for Diversification: Offers a tool for diversification due to little overlap with traditional indices. It can be a complement to traditional value/growth strategies.



Grounded in Research: Combines top-down and bottom-up research in its portfolio management to identify innovative companies and convergence across markets.



Cost Effective: Provides a lower cost alternative to mutual funds with true active management in an Exchange Traded Fund (ETF) that invests in rapidly moving themes.

SUSTAINABILITY PROFILE

As of 16 April, 2024

MSCI ESG Rating **Pending**

In both its “top down” and “bottom up” investment approaches, the Investment Manager evaluates environmental, social and governance (“ESG”) considerations.

The “top down” approach explicitly selects for technologies that the Investment Manager anticipates will have high degrees of impact on the UN SDGs. For a company to be eligible for selection, it must be involved in a technology platform that makes a “meaningful” contribution to at least two UN SDGs, as determined by the Investment Manager.

The following ESG considerations are also integrated into the “bottom up” approach:

- Business Involvement Screens (Controversial Weapons, Thermal Coal, Oil & Gas, Gambling, Adult Entertainment, Tobacco, Alcohol)
- Violations of International Norms and Standards
- Controversies
- Poor Governance

The Fund is also supported by the Investment Manager’s Engagement and Voting programmes.

FUND DETAILS

As of 16 April, 2024

ETF	ARK Genomic Revolution UCITS ETF
Type	Active Equity ETF
ISIN	IE00005M6X01
Fund Size (AUM)	\$1.00 Million
TER	0.75%
Inception Date	12 April 2024
SFDR Classification	Article 8
Holdings	40
Base Currency	USD
Income Treatment	Accumulating
Exposure	Global Equities
Domicile	Ireland
UCITS	Yes
Portfolio Manager	Catherine D. Wood
Associate Portfolio Managers	Dan White, Nicholas Grous
Issuer	ARK Invest UCITS ICAV
Promoter	ARK Invest International Ltd
Manager	IQ EQ Fund Management (Ireland) Ltd
Investment Manager	ARK Investment Management LLC
Depository / Custodian	Northern Trust Fiduciary Services (Ireland) Ltd
ISA Eligible (UK)	Yes
SIPP Eligible (UK)	Yes
Reporting Fund Status (UK)	Yes
Equity Fund (DE)	Yes

TECHNOLOGY BREAKDOWN

As of 16 April, 2024

Precision Therapies	40.9%
Multiomic Technologies	31.6%
Programmable Biology	11.1%
Neural Networks	6.4%
Next Gen Cloud	5.5%
Adaptive Robotics	2.3%
Intelligent Devices	2.0%

TRADING INFORMATION

Exchange	Currency	Listing Date	SEDOL	Bloomberg Ticker	RIC
Borsa Italiana	EUR	06 May 2024	BKVDTH7	ARKG IM	ARKG.MI
Deutsche Börse Xetra	EUR	18 April 2024	BKVDTG6	AAKG GY	AAKG.DE
CBOE Amsterdam	EUR	19 April 2024	BKVDTR7	ARKGx I2	ARKGx.DXE
London Stock Exchange	USD	19 April 2024	BKVDTC2	ARKG LN	ARKG.L
London Stock Exchange	GBP	19 April 2024	BKVDTF5	ARCG LN	ARCG.L
SIX Swiss Exchange	CHF	Pending	Pending	Pending	Pending

TOP 10 HOLDINGS

Crispr Therapeutics Ag	7.5%
Twist Bioscience Corp	6.0%
Exact Sciences Corp	5.6%
Recursion Pharmaceuticals Inc	5.1%
Schrodinger Inc/United States	4.6%
Ionis Pharmaceuticals Inc	4.3%
Beam Therapeutics Inc	4.1%
Intellia Therapeutics Inc	3.9%
Arcturus Therapeutics Holdings Inc	3.8%
10x Genomics Inc	3.7%
	48.46%

REGISTRATIONS

Austria	Italy	Sweden
Denmark	Luxembourg	United Kingdom
Finland	Netherlands	
Germany	Norway	
Ireland	Spain	

RESEARCH TEAM

Our research process is centered on utilising first principles research on disruptive technologies to inform our stock selection. Our collaboration with industry leaders through our open source research ecosystem helps us stay on the cutting edge of innovation. Our research team consists of individuals with deep domain expertise that are dedicated to specific technology areas. Stocks are analysed through these lenses of technology to inform our investment theses. Innovation Research Team: Brett Winton (Chief Futurist), Dr. Charles Roberts (Chief Investment Strategist), and broad collaboration across the research team.

TOP 10 COUNTRIES

Total may not sum to 100% due to rounding

United States	90.5%
Switzerland	7.5%
United Kingdom	1.4%
Canada	0.7%
	100.0%

MARKET CAPITALISATION

Mega (\$100B+)	3.6%
Large (\$10 - \$100B)	15.9%
Medium (\$2 - \$10B)	26.7%
Small (\$300M - \$2B)	48.5%
Micro (\$50 - \$300M)	5.3%

INVESTMENT TEAM

ARK Investment Management LLC is the investment manager for the ARK Genomic Revolution UCITS ETF and is responsible for the day-to-day investment management decisions. The team is highly experienced in all aspects relating to the management of a fund portfolio, including the execution of equities, foreign exchange and cash management. The firm's investment process begins with top-down research to identify truly disruptive innovation and sizing the opportunity. This is followed by meticulous bottom-up research and analysis, leading to the selection of portfolio companies. ARK emphasises sizing the opportunity, stock selection, valuation and risk management, ensuring a dynamic approach to capturing technologically-enabled growth whilst navigating market volatility.

RISK FACTORS

- All financial investments involve an element of risk. Therefore, the value of your investment and the income from it will vary and your initial investment amount cannot be guaranteed.
- The Fund is subject to the risks associated with technology-focused companies (including biotechnology and pharmaceutical companies) including the risk of: (1) failure of new technologies and solutions to replace existing ones or to be approved by governments/regulators or to achieve their aim; (2) the failure of individual companies to successfully capitalise on such new technologies and reach profitability; (3) competition, including rapid developments in competitive technologies (which may leave a company's products out-of-date); (4) government intervention or excessive regulation, delays to approvals or lack of financial support; and (5) legal attacks from competitors.
- Other: (1) The Fund also invests in small publicly-traded companies which may be less mature and more vulnerable to adverse business or economic events and greater share price changes than larger companies, the wider technology sector or stock market. (2) The Fund invests in global equity securities and there is a risk of loss arising from exchange rate fluctuations or exchange control regulations. (3) The ICAV's depositary or other service providers may go bankrupt and fail to return money or property belonging to the Fund. (4) It may not always be possible to buy and sell the Fund's shares on a stock exchange or at prices closely reflecting the Fund's Net Asset Value. (5) There is no capital guarantee or protection on the value of the Fund and investors can lose all the capital invested in the Fund.

Marketing Communication / Financial Promotion:

Communications issued in the European Economic Area ("EEA"): This marketing communication has been issued by IQ EQ Fund Management (Ireland) Limited ("IQ EQ") acting in its capacity as management company of ARK Invest UCITS ICAV ("ARK Invest"). IQ EQ is authorised and regulated by the Central Bank of Ireland. IQ EQ is registered in Ireland with registration number I48223.

Communications issued in jurisdictions outside of the EEA: This marketing communication has been issued by ARK Invest International Ltd ("ARK UK") which is an Appointed Representative of Aldgate Advisors Limited, a firm authorised and regulated by the Financial Conduct Authority (FCA FRN 763187). ARK UK is registered in England and Wales with registration number 11770079.

This is a marketing communication. This is not a contractually binding document. Please refer to the prospectus, Fund-specific supplement and Key Investor Information Document (the "KIID") or Key Investor Document (the "KID") (as relevant) of the relevant Fund and do not base any final investment decision on this communication alone.

You should seek professional investment advice before making any decision to invest in a Fund.

This marketing communication is not being provided to you on the basis that you are a client of IQ EQ or ARK UK. Neither IQ EQ nor ARK UK is acting on your behalf and neither entity is responsible for providing protections that would otherwise be afforded to clients of IQ EQ or ARK UK. This marketing communication is for information purposes only. Its contents, and the fact of its distribution, do not constitute investment advice, nor do they constitute tax, legal or any other form of advice or service. It does not constitute or form part of any offer to issue or sell, or the solicitation of any offer to buy or sell any investment. It shall not form the basis of, or be relied upon in connection with, any contract. Information and opinions contained herein have been compiled from sources believed to be reliable but neither IQ EQ nor ARK UK nor any of their respective partners makes any representations as to its accuracy or completeness. Any opinions, forecasts or estimates herein constitute a judgement that is subject to change without notice. IQ EQ and ARK UK disclaim all liability and responsibility arising from any reliance placed by any person on the information contained within this marketing communication.

Where past performance and projected performance information is shown, it must be noted that past performance and projected performance is not a reliable indicator of future performance. Simulated past performance does not represent actual past performance and is not a reliable indicator of future performance.

The ARK Genomic Revolution UCITS ETF is an actively managed fund which involves significant risk and is subject to the share price volatility of technology-focused companies, the risk of failure of new technologies to replace existing ones or to be approved by governments / regulators or to achieve their aim, the failure of individual companies to successfully capitalise on new technologies and reach profitability, competition, government intervention or excessive regulation, delays to approvals or lack of financial support, and legal attacks from competitors.

Capital at Risk Warning – Please note that the value of an investment and any income taken from it is not guaranteed and can go down as well as up. You may not get back the amount you originally invested. If your investment currency is different to the Funds' currency of denomination (USD) or the currencies in which the Funds' assets are denominated (which may be a range of different global currencies), then the return you will get from your investment may increase or decrease as a result of currency fluctuations between your investment currency and such currencies.

The Funds referred to in this marketing communication are offered by ARK Invest UCITS ICAV ("ARK Invest"). ARK Invest is an open-ended Irish collective asset management vehicle which is constituted as an umbrella fund with variable capital and segregated liability between its sub-funds (each, a "Fund") and registered in Ireland with registration number C193010 and authorised by the Central Bank of Ireland as a UCITS. ARK Invest is managed by IQ EQ Fund Management (Ireland) Limited ("IQ EQ"). The prospectus (including the Fund-specific supplements and other supplements), the KIIDs/KIDs the constitutional document of ARK Invest and the latest annual and semi-annual reports of ARK Invest, the latest Net Asset Values of the Funds and details of the underlying investments of the Funds (together, the "Fund Information") are available at <https://europe.ark-funds.com/>. Any decision to invest must be based solely on the Fund Information. Investors should read the Fund-specific risks in ARK Invest's prospectus, Fund-specific supplements and the KIIDs/KIDs. The indicative intra-day net asset values of the Funds are available at <http://www.solactive.com>.

The Funds are not offered or aimed at residents in any country in which (a) ARK Invest and the Funds are not authorised or registered for distribution and where to do so is contrary to the relevant country's securities laws, (b) the dissemination of information relating to ARK Invest and the Funds via the internet is forbidden, and/or IQ EQ or ARK UK are not authorised or qualified to make such offer or invitation.

The Funds may be registered or otherwise approved for distribution to the public or certain categories of investors in one or more jurisdictions. Where this is the case, a country-specific web page and copies of the Fund Information will be available at <https://europe.ark-funds.com/>. The fact of such a registration or approval, however, does not mean that any regulator (including the FCA) has determined that the Funds are suitable for all categories of investors.

United Kingdom: This is a financial promotion. For the purposes of the United Kingdom Financial Services and Markets Act 2000 ("FSMA"), ARK Invest is a UCITS that has been recognised by the Financial Conduct Authority (the "FCA") pursuant to s.264 of the UK Financial Services and Markets Act 2000. The Fund Information is available in English free of charge upon request from the Facilities Agent in the United Kingdom, FE fundinfo (UK) Limited, Unit 11, First Floor, Midas House, 62 Goldsworth Road, Woking, Surrey, GU21 6LQ, England.

Germany: This is a financial promotion. The offering of the Shares of ARK Invest has been notified to the German Financial Services Supervisory Authority (BaFin) in accordance with section 310 of the German Investment Code (KAGB). The Fund Information in English (and the KIDs in German language) can be obtained free of charge upon request from the Facilities Agent in Germany, FE fundinfo (Luxembourg) S.à.r.l., by contacting fa_gr@fefundinfo.com or in paper form at the Facilities Agent's registered office, being 77 Rue du Fossé, 4123 Esch-sur-Alzette, Luxembourg.

Switzerland: This is an advertising document. The state of the origin of the fund is Ireland. In Switzerland, the Representative in Switzerland is 1741 Fund Solutions AG, Burggraben 16, CH-9000 St. Gallen. The Paying Agent in Switzerland is Tellco AG, Bahnhofstrasse 4, 6430 Schwyz. The Fund Information may be obtained free of charge from the Representative. Past performance is no indication of current or future performance. The performance data do not take account of the commissions and costs incurred on the issue and redemption of units in the Fund.

Austria: This is a marketing communication and serves exclusively as information for investors. Under no circumstances may it replace advice regarding the acquisition and disposal of investments which may result in a total loss of the investment. The Fund Information in English (and the KIDs in German language) can be obtained free of charge upon request from the Facilities Agent in Austria, FE fundinfo (Luxembourg) S.à.r.l., by contacting fa_gr@fefundinfo.com.

United States: This marketing communication and its contents are not directed at any person that is resident in the United States ("US person"), and no offer or invitation is made to any US person to acquire or sell any service, product or security referred to. The provision of any information in this marketing communication does not constitute an offer to US persons to purchase securities.